iBio, Inc.

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, VRTX has a market cap of 109.1B. Regarding current trading prices, IBIO is priced at $1.71, while VRTX trades at $429.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas VRTX's P/E ratio is 25.51. In terms of profitability, IBIO's ROE is -0.71%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, IBIO is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check VRTX's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, REGN has a market cap of 73.6B. Regarding current trading prices, IBIO is priced at $1.71, while REGN trades at $714.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas REGN's P/E ratio is 17.44. In terms of profitability, IBIO's ROE is -0.71%, compared to REGN's ROE of +0.14%. Regarding short-term risk, IBIO is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check REGN's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, IBIO is priced at $1.71, while VRNA trades at $106.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas VRNA's P/E ratio is -102.80. In terms of profitability, IBIO's ROE is -0.71%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, IBIO is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check VRNA's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, ARGX has a market cap of 48.4B. Regarding current trading prices, IBIO is priced at $1.71, while ARGX trades at $782.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas ARGX's P/E ratio is 34.75. In terms of profitability, IBIO's ROE is -0.71%, compared to ARGX's ROE of +0.34%. Regarding short-term risk, IBIO is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check ARGX's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, IBIO is priced at $1.71, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas SGEN's P/E ratio is -57.19. In terms of profitability, IBIO's ROE is -0.71%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, IBIO is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check SGEN's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, ALNY has a market cap of 39.4B. Regarding current trading prices, IBIO is priced at $1.71, while ALNY trades at $295.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas ALNY's P/E ratio is 74.32. In terms of profitability, IBIO's ROE is -0.71%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, IBIO is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check ALNY's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, RVMD has a market cap of 30.1B. Regarding current trading prices, IBIO is priced at $1.71, while RVMD trades at $141.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas RVMD's P/E ratio is -19.95. In terms of profitability, IBIO's ROE is -0.71%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, IBIO is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check RVMD's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, UTHR has a market cap of 24B. Regarding current trading prices, IBIO is priced at $1.71, while UTHR trades at $564.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas UTHR's P/E ratio is 20.88. In terms of profitability, IBIO's ROE is -0.71%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, IBIO is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check UTHR's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, BNTX has a market cap of 23.8B. Regarding current trading prices, IBIO is priced at $1.71, while BNTX trades at $94.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas BNTX's P/E ratio is -15.85. In terms of profitability, IBIO's ROE is -0.71%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, IBIO is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check BNTX's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, INSM has a market cap of 21.9B. Regarding current trading prices, IBIO is priced at $1.71, while INSM trades at $101.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas INSM's P/E ratio is -17.59. In terms of profitability, IBIO's ROE is -0.71%, compared to INSM's ROE of -1.30%. Regarding short-term risk, IBIO is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check INSM's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, RPRX has a market cap of 21.8B. Regarding current trading prices, IBIO is priced at $1.71, while RPRX trades at $50.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas RPRX's P/E ratio is 26.73. In terms of profitability, IBIO's ROE is -0.71%, compared to RPRX's ROE of +0.11%. Regarding short-term risk, IBIO is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check RPRX's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, MRNA has a market cap of 21.6B. Regarding current trading prices, IBIO is priced at $1.71, while MRNA trades at $54.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas MRNA's P/E ratio is -6.68. In terms of profitability, IBIO's ROE is -0.71%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, IBIO is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for IBIO.Check MRNA's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, ROIV has a market cap of 20.4B. Regarding current trading prices, IBIO is priced at $1.71, while ROIV trades at $28.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas ROIV's P/E ratio is -24.41. In terms of profitability, IBIO's ROE is -0.71%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, IBIO is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check ROIV's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, IBIO is priced at $1.71, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas BGNE's P/E ratio is -22.55. In terms of profitability, IBIO's ROE is -0.71%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, IBIO is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check BGNE's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, INCY has a market cap of 19.7B. Regarding current trading prices, IBIO is priced at $1.71, while INCY trades at $98.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas INCY's P/E ratio is 13.88. In terms of profitability, IBIO's ROE is -0.71%, compared to INCY's ROE of +0.29%. Regarding short-term risk, IBIO is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check INCY's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, IBIO is priced at $1.71, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, IBIO's ROE is -0.71%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, IBIO is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check DNA-WT's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, GMAB has a market cap of 16.3B. Regarding current trading prices, IBIO is priced at $1.71, while GMAB trades at $26.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas GMAB's P/E ratio is 20.18. In terms of profitability, IBIO's ROE is -0.71%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, IBIO is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check GMAB's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, ASND has a market cap of 14.6B. Regarding current trading prices, IBIO is priced at $1.71, while ASND trades at $238.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas ASND's P/E ratio is 26.88. In terms of profitability, IBIO's ROE is -0.71%, compared to ASND's ROE of +1.28%. Regarding short-term risk, IBIO is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check ASND's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, JAZZ has a market cap of 14.2B. Regarding current trading prices, IBIO is priced at $1.71, while JAZZ trades at $225.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas JAZZ's P/E ratio is 2052.64. In terms of profitability, IBIO's ROE is -0.71%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, IBIO is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check JAZZ's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, SMMT has a market cap of 14B. Regarding current trading prices, IBIO is priced at $1.71, while SMMT trades at $18.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas SMMT's P/E ratio is -11.37. In terms of profitability, IBIO's ROE is -0.71%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, IBIO is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check SMMT's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, BBIO has a market cap of 13.1B. Regarding current trading prices, IBIO is priced at $1.71, while BBIO trades at $67.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas BBIO's P/E ratio is -18.02. In terms of profitability, IBIO's ROE is -0.71%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, IBIO is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check BBIO's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, IBIO is priced at $1.71, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas KRTX's P/E ratio is -28.09. In terms of profitability, IBIO's ROE is -0.71%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, IBIO is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check KRTX's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, IONS has a market cap of 12.5B. Regarding current trading prices, IBIO is priced at $1.71, while IONS trades at $75.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas IONS's P/E ratio is -37.67. In terms of profitability, IBIO's ROE is -0.71%, compared to IONS's ROE of -0.59%. Regarding short-term risk, IBIO is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check IONS's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, EXEL has a market cap of 12.1B. Regarding current trading prices, IBIO is priced at $1.71, while EXEL trades at $48.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas EXEL's P/E ratio is 15.95. In terms of profitability, IBIO's ROE is -0.71%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, IBIO is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check EXEL's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, MDGL has a market cap of 11.8B. Regarding current trading prices, IBIO is priced at $1.71, while MDGL trades at $510.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas MDGL's P/E ratio is -37.84. In terms of profitability, IBIO's ROE is -0.71%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, IBIO is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check MDGL's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, IBIO is priced at $1.71, while RNAM trades at $72.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas RNAM's P/E ratio is -17.39. In terms of profitability, IBIO's ROE is -0.71%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, IBIO is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check RNAM's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, AXSM has a market cap of 11.2B. Regarding current trading prices, IBIO is priced at $1.71, while AXSM trades at $217.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas AXSM's P/E ratio is -58.28. In terms of profitability, IBIO's ROE is -0.71%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, IBIO is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check AXSM's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, BMRN has a market cap of 10.4B. Regarding current trading prices, IBIO is priced at $1.71, while BMRN trades at $54.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas BMRN's P/E ratio is 38.89. In terms of profitability, IBIO's ROE is -0.71%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, IBIO is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check BMRN's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, ARWR has a market cap of 10.2B. Regarding current trading prices, IBIO is priced at $1.71, while ARWR trades at $72.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas ARWR's P/E ratio is 45.43. In terms of profitability, IBIO's ROE is -0.71%, compared to ARWR's ROE of -0.56%. Regarding short-term risk, IBIO is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check ARWR's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, CYTK has a market cap of 9.6B. Regarding current trading prices, IBIO is priced at $1.71, while CYTK trades at $76.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas CYTK's P/E ratio is -11.23. In terms of profitability, IBIO's ROE is -0.71%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, IBIO is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check CYTK's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, IBIO is priced at $1.71, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas RXDX's P/E ratio is -56.47. In terms of profitability, IBIO's ROE is -0.71%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, IBIO is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check RXDX's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, KRYS has a market cap of 9B. Regarding current trading prices, IBIO is priced at $1.71, while KRYS trades at $305.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas KRYS's P/E ratio is 40.87. In terms of profitability, IBIO's ROE is -0.71%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, IBIO is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check KRYS's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, IBRX has a market cap of 8.7B. Regarding current trading prices, IBIO is priced at $1.71, while IBRX trades at $8.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas IBRX's P/E ratio is -21.27. In terms of profitability, IBIO's ROE is -0.71%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, IBIO is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for IBIO.Check IBRX's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, IBIO is priced at $1.71, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas IMGN's P/E ratio is -111.55. In terms of profitability, IBIO's ROE is -0.71%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, IBIO is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check IMGN's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, IBIO is priced at $1.71, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas BPMC's P/E ratio is -51.58. In terms of profitability, IBIO's ROE is -0.71%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, IBIO is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check BPMC's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, IBIO is priced at $1.71, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas CERE's P/E ratio is -16.47. In terms of profitability, IBIO's ROE is -0.71%, compared to CERE's ROE of -0.72%. Regarding short-term risk, IBIO is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check CERE's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, ABVX has a market cap of 8B. Regarding current trading prices, IBIO is priced at $1.71, while ABVX trades at $122.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas ABVX's P/E ratio is -21.65. In terms of profitability, IBIO's ROE is -0.71%, compared to ABVX's ROE of -1.59%. Regarding short-term risk, IBIO is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check ABVX's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, NUVL has a market cap of 7.7B. Regarding current trading prices, IBIO is priced at $1.71, while NUVL trades at $105.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas NUVL's P/E ratio is -17.37. In terms of profitability, IBIO's ROE is -0.71%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, IBIO is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check NUVL's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, PCVX has a market cap of 7.7B. Regarding current trading prices, IBIO is priced at $1.71, while PCVX trades at $53.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas PCVX's P/E ratio is -7.69. In terms of profitability, IBIO's ROE is -0.71%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, IBIO is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check PCVX's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, HALO has a market cap of 7.6B. Regarding current trading prices, IBIO is priced at $1.71, while HALO trades at $64.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas HALO's P/E ratio is 25.05. In terms of profitability, IBIO's ROE is -0.71%, compared to HALO's ROE of +0.93%. Regarding short-term risk, IBIO is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check HALO's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, TECH has a market cap of 7.6B. Regarding current trading prices, IBIO is priced at $1.71, while TECH trades at $48.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas TECH's P/E ratio is 69.10. In terms of profitability, IBIO's ROE is -0.71%, compared to TECH's ROE of +0.05%. Regarding short-term risk, IBIO is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check TECH's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, IBIO is priced at $1.71, while MTSR trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas MTSR's P/E ratio is -23.58. In terms of profitability, IBIO's ROE is -0.71%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, IBIO is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check MTSR's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, KYMR has a market cap of 7.1B. Regarding current trading prices, IBIO is priced at $1.71, while KYMR trades at $86.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas KYMR's P/E ratio is -24.04. In terms of profitability, IBIO's ROE is -0.71%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, IBIO is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check KYMR's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, PRAX has a market cap of 7B. Regarding current trading prices, IBIO is priced at $1.71, while PRAX trades at $330.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas PRAX's P/E ratio is -24.61. In terms of profitability, IBIO's ROE is -0.71%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, IBIO is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check PRAX's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, IBIO is priced at $1.71, while MRUS trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas MRUS's P/E ratio is -17.05. In terms of profitability, IBIO's ROE is -0.71%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, IBIO is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check MRUS's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, IBIO is priced at $1.71, while ACLX trades at $115.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas ACLX's P/E ratio is -28.27. In terms of profitability, IBIO's ROE is -0.71%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, IBIO is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check ACLX's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, IBIO is priced at $1.71, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas RETA's P/E ratio is -66.29. In terms of profitability, IBIO's ROE is -0.71%, compared to RETA's ROE of +0.47%. Regarding short-term risk, IBIO is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check RETA's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, TGTX has a market cap of 6.6B. Regarding current trading prices, IBIO is priced at $1.71, while TGTX trades at $42.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas TGTX's P/E ratio is 14.99. In terms of profitability, IBIO's ROE is -0.71%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, IBIO is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check TGTX's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, RYTM has a market cap of 6.5B. Regarding current trading prices, IBIO is priced at $1.71, while RYTM trades at $94.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas RYTM's P/E ratio is -30.09. In terms of profitability, IBIO's ROE is -0.71%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, IBIO is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check RYTM's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, PTGX has a market cap of 6.4B. Regarding current trading prices, IBIO is priced at $1.71, while PTGX trades at $99.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas PTGX's P/E ratio is -54.90. In terms of profitability, IBIO's ROE is -0.71%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, IBIO is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check PTGX's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, CELC has a market cap of 6.3B. Regarding current trading prices, IBIO is priced at $1.71, while CELC trades at $131.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas CELC's P/E ratio is -29.92. In terms of profitability, IBIO's ROE is -0.71%, compared to CELC's ROE of -2.03%. Regarding short-term risk, IBIO is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check CELC's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, BLTE has a market cap of 6.2B. Regarding current trading prices, IBIO is priced at $1.71, while BLTE trades at $154.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas BLTE's P/E ratio is -67.34. In terms of profitability, IBIO's ROE is -0.71%, compared to BLTE's ROE of -0.23%. Regarding short-term risk, IBIO is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check BLTE's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, PTCT has a market cap of 6.1B. Regarding current trading prices, IBIO is priced at $1.71, while PTCT trades at $73.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas PTCT's P/E ratio is 8.59. In terms of profitability, IBIO's ROE is -0.71%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, IBIO is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for IBIO.Check PTCT's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, COGT has a market cap of 5.9B. Regarding current trading prices, IBIO is priced at $1.71, while COGT trades at $34.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas COGT's P/E ratio is -16.01. In terms of profitability, IBIO's ROE is -0.71%, compared to COGT's ROE of -0.83%. Regarding short-term risk, IBIO is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check COGT's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, CNTA has a market cap of 5.9B. Regarding current trading prices, IBIO is priced at $1.71, while CNTA trades at $39.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas CNTA's P/E ratio is -27.12. In terms of profitability, IBIO's ROE is -0.71%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, IBIO is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check CNTA's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, IMVT has a market cap of 5.9B. Regarding current trading prices, IBIO is priced at $1.71, while IMVT trades at $28.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas IMVT's P/E ratio is -10.84. In terms of profitability, IBIO's ROE is -0.71%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, IBIO is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check IMVT's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, CGON has a market cap of 5.9B. Regarding current trading prices, IBIO is priced at $1.71, while CGON trades at $69.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas CGON's P/E ratio is -33.47. In terms of profitability, IBIO's ROE is -0.71%, compared to CGON's ROE of -0.23%. Regarding short-term risk, IBIO is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check CGON's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, ALKS has a market cap of 5.8B. Regarding current trading prices, IBIO is priced at $1.71, while ALKS trades at $34.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas ALKS's P/E ratio is 38.88. In terms of profitability, IBIO's ROE is -0.71%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, IBIO is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check ALKS's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, IBIO is priced at $1.71, while CDTX trades at $221.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas CDTX's P/E ratio is -19.77. In terms of profitability, IBIO's ROE is -0.71%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, IBIO is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check CDTX's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, CORT has a market cap of 5.6B. Regarding current trading prices, IBIO is priced at $1.71, while CORT trades at $52.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas CORT's P/E ratio is 149.37. In terms of profitability, IBIO's ROE is -0.71%, compared to CORT's ROE of +0.08%. Regarding short-term risk, IBIO is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check CORT's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, SRRK has a market cap of 5.6B. Regarding current trading prices, IBIO is priced at $1.71, while SRRK trades at $48.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas SRRK's P/E ratio is -14.71. In terms of profitability, IBIO's ROE is -0.71%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, IBIO is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check SRRK's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, IBIO is priced at $1.71, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, IBIO's ROE is -0.71%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, IBIO is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check ABCM's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, IBIO is priced at $1.71, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas ISEE's P/E ratio is -22.44. In terms of profitability, IBIO's ROE is -0.71%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, IBIO is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check ISEE's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, MIRM has a market cap of 5.4B. Regarding current trading prices, IBIO is priced at $1.71, while MIRM trades at $107.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas MIRM's P/E ratio is -7.88. In terms of profitability, IBIO's ROE is -0.71%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, IBIO is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check MIRM's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, CRSP has a market cap of 5.3B. Regarding current trading prices, IBIO is priced at $1.71, while CRSP trades at $54.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas CRSP's P/E ratio is -8.89. In terms of profitability, IBIO's ROE is -0.71%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, IBIO is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check CRSP's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, IBIO is priced at $1.71, while APLS trades at $41.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas APLS's P/E ratio is 38.36. In terms of profitability, IBIO's ROE is -0.71%, compared to APLS's ROE of +0.40%. Regarding short-term risk, IBIO is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check APLS's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, LEGN has a market cap of 5.2B. Regarding current trading prices, IBIO is priced at $1.71, while LEGN trades at $28.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas LEGN's P/E ratio is -17.36. In terms of profitability, IBIO's ROE is -0.71%, compared to LEGN's ROE of -0.29%. Regarding short-term risk, IBIO is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check LEGN's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, FBIOX has a market cap of 5.2B. Regarding current trading prices, IBIO is priced at $1.71, while FBIOX trades at $25.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas FBIOX's P/E ratio is N/A. In terms of profitability, IBIO's ROE is -0.71%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, IBIO is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check FBIOX's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, APGE has a market cap of 5.1B. Regarding current trading prices, IBIO is priced at $1.71, while APGE trades at $83.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas APGE's P/E ratio is -19.68. In terms of profitability, IBIO's ROE is -0.71%, compared to APGE's ROE of -0.37%. Regarding short-term risk, IBIO is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check APGE's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, IBIO is priced at $1.71, while TERN trades at $52.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas TERN's P/E ratio is -51.41. In terms of profitability, IBIO's ROE is -0.71%, compared to TERN's ROE of -0.20%. Regarding short-term risk, IBIO is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check TERN's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, CAI has a market cap of 4.6B. Regarding current trading prices, IBIO is priced at $1.71, while CAI trades at $16.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas CAI's P/E ratio is -5.02. In terms of profitability, IBIO's ROE is -0.71%, compared to CAI's ROE of +0.06%. Regarding short-term risk, IBIO is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for IBIO.Check CAI's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, IBIO is priced at $1.71, while FOLD trades at $14.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas FOLD's P/E ratio is -161.00. In terms of profitability, IBIO's ROE is -0.71%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, IBIO is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check FOLD's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, SYRE has a market cap of 4.5B. Regarding current trading prices, IBIO is priced at $1.71, while SYRE trades at $75.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas SYRE's P/E ratio is -35.40. In terms of profitability, IBIO's ROE is -0.71%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, IBIO is more volatile compared to SYRE. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check SYRE's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, NAMS has a market cap of 4.5B. Regarding current trading prices, IBIO is priced at $1.71, while NAMS trades at $38.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas NAMS's P/E ratio is -21.76. In terms of profitability, IBIO's ROE is -0.71%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, IBIO is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for IBIO.Check NAMS's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, IBIO is priced at $1.71, while AKRO trades at $54.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas AKRO's P/E ratio is -14.57. In terms of profitability, IBIO's ROE is -0.71%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, IBIO is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check AKRO's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, IBIO is priced at $1.71, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas ALPN's P/E ratio is -101.52. In terms of profitability, IBIO's ROE is -0.71%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, IBIO is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check ALPN's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, XENE has a market cap of 4.5B. Regarding current trading prices, IBIO is priced at $1.71, while XENE trades at $56.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas XENE's P/E ratio is -12.94. In terms of profitability, IBIO's ROE is -0.71%, compared to XENE's ROE of -0.48%. Regarding short-term risk, IBIO is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check XENE's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, LGND has a market cap of 4.4B. Regarding current trading prices, IBIO is priced at $1.71, while LGND trades at $221.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas LGND's P/E ratio is 36.12. In terms of profitability, IBIO's ROE is -0.71%, compared to LGND's ROE of +0.16%. Regarding short-term risk, IBIO is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check LGND's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, MANE has a market cap of 4.4B. Regarding current trading prices, IBIO is priced at $1.71, while MANE trades at $106.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas MANE's P/E ratio is -44.48. In terms of profitability, IBIO's ROE is -0.71%, compared to MANE's ROE of -0.76%. Regarding short-term risk, IBIO is more volatile compared to MANE. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check MANE's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, KNSA has a market cap of 4.3B. Regarding current trading prices, IBIO is priced at $1.71, while KNSA trades at $58.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas KNSA's P/E ratio is 61.68. In terms of profitability, IBIO's ROE is -0.71%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, IBIO is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check KNSA's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, IBIO is priced at $1.71, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas OPT's P/E ratio is -1.52. In terms of profitability, IBIO's ROE is -0.71%, compared to OPT's ROE of +0.88%. Regarding short-term risk, IBIO is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check OPT's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, IBIO is priced at $1.71, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas MRTX's P/E ratio is -4.82. In terms of profitability, IBIO's ROE is -0.71%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, IBIO is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check MRTX's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, TVTX has a market cap of 4B. Regarding current trading prices, IBIO is priced at $1.71, while TVTX trades at $42.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas TVTX's P/E ratio is -85.20. In terms of profitability, IBIO's ROE is -0.71%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, IBIO is more volatile compared to TVTX. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check TVTX's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, CRNX has a market cap of 3.9B. Regarding current trading prices, IBIO is priced at $1.71, while CRNX trades at $37.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas CRNX's P/E ratio is -7.57. In terms of profitability, IBIO's ROE is -0.71%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, IBIO is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for IBIO.Check CRNX's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, ACAD has a market cap of 3.8B. Regarding current trading prices, IBIO is priced at $1.71, while ACAD trades at $22.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas ACAD's P/E ratio is 10.14. In terms of profitability, IBIO's ROE is -0.71%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, IBIO is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check ACAD's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, CPRX has a market cap of 3.8B. Regarding current trading prices, IBIO is priced at $1.71, while CPRX trades at $31.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas CPRX's P/E ratio is 18.54. In terms of profitability, IBIO's ROE is -0.71%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, IBIO is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check CPRX's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, EWTX has a market cap of 3.8B. Regarding current trading prices, IBIO is priced at $1.71, while EWTX trades at $35.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas EWTX's P/E ratio is -21.28. In terms of profitability, IBIO's ROE is -0.71%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, IBIO is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check EWTX's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, IBIO is priced at $1.71, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas RYZB's P/E ratio is -57.86. In terms of profitability, IBIO's ROE is -0.71%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, IBIO is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check RYZB's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, LQDA has a market cap of 3.7B. Regarding current trading prices, IBIO is priced at $1.71, while LQDA trades at $42.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas LQDA's P/E ratio is -52.98. In terms of profitability, IBIO's ROE is -0.71%, compared to LQDA's ROE of -2.09%. Regarding short-term risk, IBIO is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check LQDA's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, IBIO is priced at $1.71, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas CBAY's P/E ratio is -32.81. In terms of profitability, IBIO's ROE is -0.71%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, IBIO is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check CBAY's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, VKTX has a market cap of 3.6B. Regarding current trading prices, IBIO is priced at $1.71, while VKTX trades at $31.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas VKTX's P/E ratio is -7.55. In terms of profitability, IBIO's ROE is -0.71%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, IBIO is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check VKTX's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, TLX has a market cap of 3.6B. Regarding current trading prices, IBIO is priced at $1.71, while TLX trades at $10.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas TLX's P/E ratio is -534.00. In terms of profitability, IBIO's ROE is -0.71%, compared to TLX's ROE of -0.02%. Regarding short-term risk, IBIO is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check TLX's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, IBIO is priced at $1.71, while SWTX trades at $46.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas SWTX's P/E ratio is -13.78. In terms of profitability, IBIO's ROE is -0.71%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, IBIO is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check SWTX's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, DNTH has a market cap of 3.3B. Regarding current trading prices, IBIO is priced at $1.71, while DNTH trades at $86.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas DNTH's P/E ratio is -20.63. In terms of profitability, IBIO's ROE is -0.71%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, IBIO is more volatile compared to DNTH. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check DNTH's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, BEAM has a market cap of 3.3B. Regarding current trading prices, IBIO is priced at $1.71, while BEAM trades at $32.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas BEAM's P/E ratio is -65.96. In terms of profitability, IBIO's ROE is -0.71%, compared to BEAM's ROE of -0.06%. Regarding short-term risk, IBIO is more volatile compared to BEAM. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check BEAM's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, VCYT has a market cap of 3.2B. Regarding current trading prices, IBIO is priced at $1.71, while VCYT trades at $40.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas VCYT's P/E ratio is 37.44. In terms of profitability, IBIO's ROE is -0.71%, compared to VCYT's ROE of +0.07%. Regarding short-term risk, IBIO is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check VCYT's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, NAMSW has a market cap of 3.2B. Regarding current trading prices, IBIO is priced at $1.71, while NAMSW trades at $28.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas NAMSW's P/E ratio is N/A. In terms of profitability, IBIO's ROE is -0.71%, compared to NAMSW's ROE of -0.30%. Regarding short-term risk, IBIO is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check NAMSW's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, ERAS has a market cap of 3.1B. Regarding current trading prices, IBIO is priced at $1.71, while ERAS trades at $10.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas ERAS's P/E ratio is -23.00. In terms of profitability, IBIO's ROE is -0.71%, compared to ERAS's ROE of -0.34%. Regarding short-term risk, IBIO is more volatile compared to ERAS. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check ERAS's competition here

IBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IBIO stands at 27M. In comparison, DNLI has a market cap of 3.1B. Regarding current trading prices, IBIO is priced at $1.71, while DNLI trades at $19.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IBIO currently has a P/E ratio of -1.71, whereas DNLI's P/E ratio is -6.61. In terms of profitability, IBIO's ROE is -0.71%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, IBIO is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for IBIO.Check DNLI's competition here